Ionis Pharmaceuticals, Inc.
MODULATORS OF IRF5 EXPRESSION
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF5 expression, which may be useful for treating, preventing, or ameliorating a disease associated with IRF5.
Status:
Application
Type:
Utility
Filling date:
3 Nov 2021
Issue date:
17 Feb 2022